When looking at options for weight management, finding the right fit comes down to understanding how each medication works. Wegovy® is a prescription weight loss medication, and Alli® is an over-the-counter (OTC) option. While the FDA approves both Wegovy® and Alli® to support weight loss, each of these drugs works through different mechanisms in your body.

Here, we’ll compare Wegovy® versus Alli® across effectiveness, daily management, and safety profiles to guide a more informed conversation with your healthcare provider.

‍

Wegovy® vs. Alli®: Key differences at a glance

Wegovy® is a prescription medication that’s FDA-approved for chronic weight management. Its active ingredient, semaglutide, belongs to a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

Alli® is the brand name for the only FDA-approved over-the-counter (OTC) drug for weight loss. Its active ingredient, orlistat, belongs to a class of medications called lipase inhibitors.

Here’s a side-by-side breakdown: 

‍

Wegovy® vs. Alli®: How do they work?

While both drugs can help with weight loss, they work through different mechanisms in your body.

Wegovy® (semaglutide)

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone your gut releases after you eat. Because it mimics GLP-1, semaglutide triggers a cascade of metabolic events:

• Cues your pancreas to release insulin only when your blood sugar levels are rising. This helps move glucose out of the blood and into the cells, where it can be used for energy.

• Blocks the hormone (glucagon) that tells the liver to release stored sugar (glucose) into the bloodstream. This action regulates glucose release, preventing unnecessary blood sugar spikes between meals and after exercise.
• Physically slows down how fast food leaves your stomach and enters the small intestine. This keeps you full longer after eating. 
• Interacts directly with the appetite-regulating center of the brain (hypothalamus) to reduce overall appetite. This makes you less likely to overeat.

Alli® (orlistat)

Orlistat is an OTC lipase inhibitor that contains half the dosage of its prescription counterpart, Xenical®. The medication acts locally within your digestive tract and:

• Inhibits gastrointestinal enzymes that break down dietary fat (lipases) in the stomach and small intestine. This stops about 25% of the fat you eat from being broken down into absorbable molecules.
• Directs the unabsorbed fat to remain in your digestive tract instead of entering the bloodstream. This fat then exits your body through bowel movements.
• Prevents a portion of the fat calories in your meals from being stored or used by the body. This leads to an overall reduction in calorie intake when paired with a low-fat diet. 

‍

Weight loss efficacy with Wegovy® vs. Alli®

When comparing Wegovy® versus Alli®, clinical research consistently shows that Wegovy® usually leads to more weight loss. The difference comes down to how each medication alters your body’s biology and appetite. Wegovy® reduces hunger and caloric intake, while Alli® blocks dietary fat locally. If you don’t follow a reduced-calorie, low-fat diet, Alli® will likely have a minimal impact on weight loss. 

Below, we’ll cover key clinical trial outcomes for both drugs.

Wegovy® STEP-1 trial

The STEP 1 trial played a key role in demonstrating Wegovy’s® efficacy for chronic weight management. This 68-week trial followed 1,961 non-diabetic adults with a body mass index (BMI) of 30 or higher, or a BMI of at least 27 with a weight-related condition like high blood pressure. Here are the weight loss results across percent of body fat:

‍

Alli® double-blind trial

A double-blind trial published in the Annals of Pharmacotherapy helped demonstrate Alli®’s efficacy. Researchers gave participants (391 adults with a BMI over 25) 60 mg of orlistat three times daily or a placebo over 16 weeks. Here are the results:

‍

Weight loss with Alli® tends to plateau around the 5% mark between 16 weeks and six months.

Wegovy® vs. Alli®: Side effects and risks

Both Wegovy® and Alli® carry distinct side effects and risk profiles.

Side effects

Common side effects of semaglutide and orlistat are primarily gastrointestinal: 

• Wegovy® (semaglutide) side effects include nausea, diarrhea, and vomiting.
• Alli® (orlistat) side effects include gas with oily spotting, loose stools, and more frequent bowel movements. 

Contraindications

Contraindications represent a condition you have, or a circumstance you’re in, that makes a medication unsafe to use. Wegovy® and Alli® both have established contraindications. If one applies to you, your doctor can walk you through alternatives.

Wegovy® (semaglutide) contraindications 

• A personal or family history of medullary thyroid cancer
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Allergy to semaglutide or any ingredient in Wegovy®
• Pregnancy or a plan to become pregnant

Alli® (orlistat) contraindications 

• Taking cyclosporine
• Having received an organ transplant 
• Diagnosed problems absorbing food (chronic malabsorption)
• Pregnancy or breastfeeding
• Allergy to any ingredient in orlistat capsules 

Serious side effects

A black box warning is the FDA’s strongest safety warning. It’s reserved for risks that can lead to serious injury or death. 

Wegovy® carries one black box warning: thyroid C-cell tumors. This warning comes from rodent studies showing that high doses of GLP-1 RAs increased absolute C-cell counts by 0–27.8%. It’s important to note that rodents have a high density of GLP-1 receptors on thyroid C-cells compared to humans, making them uniquely sensitive to GLP-1 RA-induced C-cell stimulation. However, human reviews show that incidence of thyroid cancer among patients was less than 1%. Before prescribing Wegovy® and as you progress through your care plan, your doctor will screen for this through blood testing and imaging if you have a family history of endocrine tumors. 

Alli® does not carry any boxed warnings. However, in June 2026, the FDA updated its label to warn of rare acute kidney injury and kidney stones. They now advise those who’ve had kidney disease or kidney stones to speak with a healthcare provider before using Alli®. They also caution patients to stop treatment and contact a doctor if relevant symptoms arise. These include groin pain, painful urination, and blood in urine.

‍

Who should use Wegovy® vs. Alli®?

Meeting baseline BMI criteria makes someone eligible for a medication like Wegovy®, but it doesn’t automatically mean they’re a good candidate. A comprehensive specialist evaluation looks beyond the scale, reviewing your complete medical history—including contraindications, current medications, and pregnancy plans. For individuals with uteruses, evaluation should also assess underlying metabolic drivers like thyroid function, Polyendocrine Metabolic Ovarian Syndrome (PMOS), or perimenopause. These factors can impact how your body responds to medications. For example, hormone fluctuations can cause additional side effects like nausea and fatigue, which can compound the gastrointestinal discomfort experienced on Wegovy®. 

Adults diagnosed with obesity or who have a BMI of 27 or greater alongside a weight-related health complication like high blood pressure can benefit from Wegovy®. Those managing specific conditions like established cardiovascular disease or metabolic dysfunction-associated steatohepatitis (MASH) can also benefit. However, Wegovy® is only available by prescription. 

Individuals seeking an OTC alternative may be a better fit for Alli®. However, you must be able to commit to taking the capsules alongside meals while also maintaining a reduced-calorie, low-fat diet. Keep in mind that while OTC options like Alli® don’t require a formal doctor’s eligibility check before purchase, it’s best to consult your physician before trying any new medication.

‍

Compassionate, evidence-based GLP-1 care

Choosing between treatment options like Wegovy® and Alli® isn’t a decision you should have to make alone. At Maven Clinic, our team of specialists will look at your full health picture to tailor a plan to your specific needs. We support your journey from every angle, delivering compassionate, evidence-based care. 

As one of our patients, Sarah, expressed: "My provider was incredibly helpful. Understood my goals and is helping me meet them. Incredibly affirming, kind, supportive, and makes sure I have the facts and data." 

Discover our approach to GLP-1 care. 

‍